Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1987 2
1988 7
1989 4
1990 8
1991 9
1992 16
1993 5
1994 17
1995 40
1996 70
1997 89
1998 117
1999 151
2000 179
2001 159
2002 174
2003 159
2004 203
2005 158
2006 234
2007 246
2008 296
2009 431
2010 473
2011 499
2012 532
2013 516
2014 439
2015 477
2016 498
2017 496
2018 523
2019 205
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

6,712 results
Results by year
Filters applied: . Clear all
Page 1
Platelet Inhibitors.
Shifrin MM and Widmar SB. Nurs Clin North Am 2016 - Review. PMID 26897422
Platelet adhesion, activation, and aggregation are essential components of platelet function; platelet-inhibiting medications interfere with these components and reduce incidence of thrombosis. Active bleeding is a contraindication for administration of platelet inhibitors. There is currently no reversal agent for platelet inhibitors, although platelet transfusion may be used to correct active bleeding after administration of platelet inhibitors....
Platelet adhesion, activation, and aggregation are essential components of platelet function; platelet-inhibitin
[Platelet function tests: tailored antiplatelet therapy for vascular patients?].
Brand ART, et al. Ned Tijdschr Geneeskd 2017 - Review. PMID 29219795 Dutch.
- Platelet aggregation inhibitors, also known as antiplatelet therapy (APT), are prescribed for the prevention of secondary cardiovascular events (CVE) after endovascular revascularization procedures.- Platelet aggregation inhibitors are not equally effective in all patients. The phenomenon of high residual platelet reactivity despite APT is called 'high on-treatment platelet reactivity' (HTPR); it bears an increased risk of secondary CVE.- Platelet function tests (PFT) can be used to diagnose HTPR. ...
- Platelet aggregation inhibitors, also known as antiplatelet therapy (APT), are prescribed for the prevention of secon …
Goal-driven management of interacting clinical guidelines for multimorbidity patients
Kogan A, et al. AMIA Annu Symp Proc 2018. PMID 30815111 Free PMC article.
We are developing a goal-based method that utilizes knowledge of drugs' physiological effects and therapeutic usage to combine knowledge from CIGs. ...Our algorithm uses patterns to check consistency and respond to events, including data enquiries, diagnoses, adverse events, recommended medications, tests, and goals. ...
We are developing a goal-based method that utilizes knowledge of drugs' physiological effects and therapeutic usage to combine knowle …
Concomitant use of proton pump inhibitors and dual antiplatelet therapy for cardiovascular outcomes.
Mandurino-Mirizzi A, et al. Minerva Endocrinol 2017 - Review. PMID 27808485
EVIDENCE SYNTHESIS: Several systematic reviews and meta-analyses suggest an increased risk of major adverse cardiovascular events (MACE), but not of mortality in patients with concomitant use of PPIs and clopidogrel. Two meta-analysis studying the interactions between individual PPIs and clopidogrel failed to demonstrate any strong relationships with adverse CV outcomes. ...
EVIDENCE SYNTHESIS: Several systematic reviews and meta-analyses suggest an increased risk of major adverse cardiovascular events (MA …
The use of platelet reactivity testing in patients on antiplatelet therapy for prediction of bleeding events after cardiac surgery.
Leunissen TC, et al. Vascul Pharmacol 2016 - Review. PMID 26724555
Many patients are treated with platelet inhibitors such as aspirin and clopidogrel for prevention of thrombotic cardiovascular events. ...The newer and more potent platelet inhibitors, prasugrel and ticagrelor, often lead to low platelet reactivity, which potentially leads to bleeding events. ...
Many patients are treated with platelet inhibitors such as aspirin and clopidogrel for prevention of thrombotic cardiovascular …
Foreword
Ventura H. Curr Probl Cardiol 2017. PMID 28363583
6,712 results
Jump to page
Feedback